Tempus announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157). The collaboration builds on joint efforts initiated last year ...

Recursion Pharmaceuticals Inc. stocks have been trading up by 15.41 percent amid heightened optimism over its AI-driven drug ...

Tempus AI Inc. stocks have been trading up by 6.55 percent after bullish coverage on its AI-driven healthcare data platform.

Researchers have developed IGA, an unsupervised graph alignment framework that uses isomorphism-aware neural networks to ...

A new graph-based framework translates RNA sequences into physicochemical interaction graphs, delivering interpretable ...

Richard Socher, co-founder and CEO of Recursive, argues on the Peter Diamandis podcast that while weak forms of recursive self-improvement ...

"My child has been attending a major programming school since elementary school for three years and can now create games ...

Knowledge graphs give Blitzy's autonomous coding agents the context needed to safely modify large, complex enterprise ...

Humans are the ones building AI.Until now, I thought that was a given.However, looking at the internal data released by ...

The revised Tempus contract extends to six years, removing Recursion Pharmaceuticals’ right to terminate for convenience.

Recursion Pharmaceuticals will pay Tempus $42 million over the next three years under a data license agreement. The companies extended their data partnership, first signed in 2023, through November ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...